thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
== Uses == BPF is used in the manufacture of plastics and epoxy resins. It is used in the production of tank and pipe linings, industrial flooring, road and bridge deck toppings, structural adhesives, grouts, coatings and electrical varnishes. BPF is also utilized in liners, lacquers, adhesives, plastics, and the coating of drinks and food cans. BPF is found in dental materials, such as restorative materials, liners, adhesives, oral prosthetic devices and tissue substitutes.
=== Founding the Respect Party === Galloway wrote in an article for The Guardian at the end of October 2003 that he would soon be part of a coalition consisting of the "red, green, anti-war, Muslim and other social constituencies radicalised by the war." In January 2004, it emerged that Galloway would be working with the Socialist Workers Party in England and Wales, and others, under the name Respect – The Unity Coalition, generally referred to simply as "Respect". In the opinion of Nick Cohen of The Observer it was an "alliance ... between the Trotskyist far left and the Islamic far right." Galloway announced in December 2003 that he would not force a by-election and did not intend to contest the next general election in Glasgow. His Glasgow Kelvin seat was to be split between three constituencies for the next general election. In one of these, the new Glasgow Central constituency, Mohammad Sarwar, the first Muslim Labour MP, wanted to be selected as the candidate. Galloway chose not to challenge him, announcing this decision at the end of May 2004 in his Mail on Sunday column.
=== Emigration === In an interview with VICE News' Krishna Andavolu shortly after Bukele's inauguration, he said that he "share[s] the same concern President Trump [has with] immigration, but for different reasons [...] [Trump] doesn't want our people to go; I don't want our people to leave." In a 2021 interview on Fox News' Tucker Carlson Tonight, Bukele attributed mass emigration from Central America to the United States to the region's "lack of economic opportunity" and "lack of security" and described the level of emigration to the United States as "immoral". He argued that emigration strained the United States and impeded domestic efforts to improve living conditions in El Salvador.
August 19 – Jessica Bowie, a 35-year-old woman, is arrested over an alleged Islamic State-inspired terrorist attack on the New York State capital. August 20 Declaring "economic D-day," Trump announces that any nation trading with Iran will be sanctioned. Reuters reports that more than 150 Polymarket wallets may have traded using non-public U.S. military information. The Asia-based USS George Washington replaces Abraham Lincoln. August 22 The Trump administration informs Congress that it intends to pay $850 million of the several billion dollars it owes the UN, the highest payment the administration has made to the international body since demanding major reforms in exchange for ongoing support as its largest donor. 50% tariffs are imposed by the Trump administration on Canadian exports. A court in New York overturns the Trump policy of suspending the processing of immigration visas from 75 nations. Far-right activist Jake Lang, who was pardoned last year for his role in the January 6 riot at the United States Capitol, is arrested during a protest in Minneapolis, Minnesota. August 23 – The Freedom 250 Grand Prix is held at the National Mall as part of the United States Semiquincentennial celebrations. August 24 US Treasury Secretary Scott Bessent announces a new U.S. sanctions campaign against the Iranian government dubbed Operation Economic Outcast, warning that every country has a set deadline to halt economic activities with the government identified by Washington or risk Treasury action that includes the removal of the US dollar financial system.
Sources: en.wikipedia.org
== Function == LRP5 acts as a co-receptor with LRP6 and the Frizzled protein family members for transducing signals by Wnt proteins through the canonical Wnt pathway. This protein plays a key role in skeletal homeostasis.
The four-engined Fw 200 airliner flew nonstop between Berlin and New York City on 10 August 1938, making the journey in 24 hours and 56 minutes. It was the first aircraft to fly that route without stopping. The return trip on 13 August 1938, took 19 hours and 47 minutes. These flights are commemorated with a plaque in the Böttcherstraße street of Bremen. The Fw 190 Würger (Shrike/butcher-bird), designed from 1938 on, and produced in quantity from early 1941–1945, was a mainstay single-seat fighter for the Luftwaffe during World War II.
=== Quantum dots === Graphene quantum dots (GQDs) keep all dimensions less than 10 nm. Their size and edge crystallography govern their electrical, magnetic, optical, and chemical properties. GQDs can be produced via graphite nanotomy or via bottom-up, solution-based routes (Diels-Alder, cyclotrimerization and/or cyclodehydrogenation reactions). GQDs with controlled structure can be incorporated into applications in electronics, optoelectronics and electromagnetics. Quantum confinement can be created by changing the width of graphene nanoribbons (GNRs) at selected points along the ribbon. It is studied as a catalyst for fuel cells.
However, this cannot be seen in experiments and the model has been widely rejected. The most accepted view is that the TCR engages in kinetic proofreading. The kinetic proofreading model proposes that a signal is not directly produced upon binding but a series of intermediate steps ensure a time delay between binding and signal output. Such intermediate "proofreading" steps can be multiple rounds of tyrosine phosphorylation. These steps require energy and therefore do not happen spontaneously, only when the receptor is bound to its ligand. This way only ligands with high affinity that bind the TCR for a long enough time can initiate a signal. All intermediate steps are reversible, such that upon ligand dissociation the receptor reverts to its original unphosphorylated state before a new ligand binds. This model predicts that maximum response of T cells decreases for pMHC with shorter lifetime. Experiments have confirmed this model. However, the basic kinetic proofreading model has a trade-off between sensitivity and specificity. Increasing the number of proofreading steps increases the specificity but lowers the sensitivity of the receptor. The model is therefore not sufficient to explain the high sensitivity and specificity of TCRs that have been observed. (Altan Bonnet2005) Multiple models that extend the kinetic proofreading model have been proposed, but evidence for the models is still controversial. The antigen sensitivity is higher in antigen-experienced T cells than in naive T cells.
== Osteopathies, chondropathies, and acquired musculoskeletal deformities (730–739) == 730 Osteomyelitis, periostitis, and other infections involving bone 731 Osteitis deformans and osteopathies associated with other disorders 732 Osteochondropathies 732.7 Osteochondritis dissecans 733 Other disorders of bone and cartilage 733.0 Osteoporosis 733.1 Pathologic fracture 733.2 Cyst of bone 733.3 Hyperostosis of skull 733.4 Aseptic necrosis of bone 733.5 Osteitis condensans 733.6 Tietze's disease Costochondritis 733.7 Algoneurodystrophy 733.8 Malunion and nonunion of fracture 733.9 Other and unspecified disorders of bone and cartilage 733.90 Disorder of bone and cartilage, unspecified Osteopenia Ostealgia 733.92 Chondromalacia 734 Flat foot 735 Acquired deformities of toe 735.0 Hallux valgus 735.2 Hallux rigidus 735.4 Hammer toe, other 736 Other acquired deformities of limbs 736.1 Mallet finger 736.2 Other acquired deformities of finger 736.7 Other acquired deformities of ankle and foot 736.8 Acquired deformities of other parts of limbs 736.81 Unequal leg length (acquired) 736.89 Other acquired deformity of other parts of limb Winged scapula 736.9 Acquired deformity, limb, unspec. 737 Curvature of spine 737.1 Kyphosis (acquired) 737.2 Lordosis (acquired) 737.3 Scoliosis 737.9 Kyphosis/scoliosis, unspec.
Sources: en.wikipedia.org
The prothrombin time (PT) – along with its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) – is an assay for evaluating the extrinsic pathway and common pathway of coagulation. This blood test is also called protime INR and PT/INR. They are used to determine the clotting tendency of blood, in conditions such as the measure of warfarin dosage, liver damage (cirrhosis), and vitamin K status. PT measures the following coagulation factors: I (fibrinogen), II (prothrombin), V (proaccelerin), VII (proconvertin), and X (Stuart–Prower factor). PT is often used in conjunction with the activated partial thromboplastin time (aPTT) which measures the intrinsic pathway and common pathway of coagulation.
Isotretinoin is a teratogen highly likely to cause birth defects if taken by women during pregnancy or even a short time before conception. A few of the more common birth defects this drug can cause are hearing and visual impairment, missing or malformed earlobes, facial dysmorphism, and abnormalities in brain function. Isotretinoin is classified as FDA Pregnancy Category X and ADEC Category X, and use is contraindicated in pregnancy. In the EU, isotretinoin (oral) is contraindicated in pregnancy and must not be taken by women able to have children unless the conditions of a pregnancy prevention program are met. The manufacturer recommends pregnancy be ruled out two weeks before commencement of isotretinoin, and women should use two simultaneous forms of effective contraception at least one month before commencement, during, and for at least one month following isotretinoin therapy. In the US, around 2000 women became pregnant while taking the drug between 1982 and 2000, with most pregnancies ending in abortion or miscarriage. About 160 babies with birth defects were born. After the FDA put the more strict iPLEDGE program in place for the companies marketing the drug in the US, in 2011, 155 pregnancies occurred (0.12%) among 129,544 women of childbearing potential taking isotretinoin. People taking isotretinoin are advised against donating blood during and for at least one month after treatment due to its teratogenicity.
In fact, John Zhu, a professor at the University of Queensland, is exploring the creation of a carbon nanotube(CNT) which can trap greenhouse gases hundreds of times more efficiently than current methods can.
19 October – The SNP appoints Carol Beattie, a former chief executive of Stirling Council, as interim chief executive following the resignation of Murray Foote. 20 October – The UK government announces plans to appoint a minister to oversee the building of HS2, as well as confirming it will not reinstate the route's Birmingham to Manchester leg. The Sunday Times reports that Rushanara Ali has given up responsibility for managing building safety after survivors of the Grenfell tower fire called for her to stand down following an article that highlighted her attendance at the Franco-British Colloque, a conference that brings together senior politicians, civil servants and business leaders. 21 October – A Freedom of Information request reveals that Suella Braverman sent government documents to her private email account 127 times while she was Attorney General, potentially breaching the ministerial code. 22 October – The Welsh Government pays a £19m tax bill for the environment agency, Natural Resources Wales, following a HM Revenue and Customs investigation into how the agency hired specialist contractors. The UK signs what it has described as a "landmark defence agreement" with Germany. 23 October – Charles III and Camilla arrive in Samoa for a state visit, where the King will preside over the 2024 Commonwealth Heads of Government Meeting. The Senedd votes 26–19 to defeat a motion calling for a new law to allow assisted dying in England and Wales.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.